JP2023550191A5 - - Google Patents
Info
- Publication number
- JP2023550191A5 JP2023550191A5 JP2023531563A JP2023531563A JP2023550191A5 JP 2023550191 A5 JP2023550191 A5 JP 2023550191A5 JP 2023531563 A JP2023531563 A JP 2023531563A JP 2023531563 A JP2023531563 A JP 2023531563A JP 2023550191 A5 JP2023550191 A5 JP 2023550191A5
- Authority
- JP
- Japan
- Prior art keywords
- nanocage
- fusion protein
- monomer
- subunit
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063118306P | 2020-11-25 | 2020-11-25 | |
| US63/118,306 | 2020-11-25 | ||
| PCT/CA2021/051690 WO2022109743A1 (en) | 2020-11-25 | 2021-11-25 | Polypeptides targeting dr4 and/or dr5 and related compositions and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023550191A JP2023550191A (ja) | 2023-11-30 |
| JP2023550191A5 true JP2023550191A5 (cg-RX-API-DMAC7.html) | 2024-12-02 |
Family
ID=81753696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023531563A Pending JP2023550191A (ja) | 2020-11-25 | 2021-11-25 | Dr4および/またはdr5を標的とするポリペプチドならびに関連する組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240182544A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4251654A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023550191A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230116833A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116917339A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021386892A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3202378A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023006148A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022109743A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024003139A (es) * | 2021-09-13 | 2024-06-24 | Hospital For Sick Children | Multabody dirigido a dr5 para el tratamiento del cancer. |
| WO2024050648A1 (en) * | 2022-09-11 | 2024-03-14 | Radiant Biotherapeutics Inc. | Treatment of chemo-resistant tumors using multabodies |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX391162B (es) * | 2015-10-30 | 2025-03-21 | Galaxy Biotech Llc | Anticuerpos altamente potentes que se unen a receptor de muerte 4 y receptor de muerte 5 |
| CA3071922A1 (en) * | 2017-08-04 | 2019-02-07 | The Governing Council Of The University Of Toronto | Nanoparticle platform for antibody and vaccine delivery |
| KR102348838B1 (ko) * | 2019-03-07 | 2022-01-11 | 경북대학교 산학협력단 | 트레일 트라이머와 암표적 펩타이드를 멀티디스플레이하는 페리틴 나노케이지 및 이의 항암제로서의 용도 |
| CA3136730A1 (en) * | 2019-04-25 | 2020-10-29 | The Regents Of The University Of California | Self-assembling protein nanocage decorated with antibodies (sapna) and parts thereof |
-
2021
- 2021-11-25 JP JP2023531563A patent/JP2023550191A/ja active Pending
- 2021-11-25 CN CN202180087906.XA patent/CN116917339A/zh active Pending
- 2021-11-25 WO PCT/CA2021/051690 patent/WO2022109743A1/en not_active Ceased
- 2021-11-25 KR KR1020237020902A patent/KR20230116833A/ko active Pending
- 2021-11-25 US US18/253,483 patent/US20240182544A1/en active Pending
- 2021-11-25 CA CA3202378A patent/CA3202378A1/en active Pending
- 2021-11-25 MX MX2023006148A patent/MX2023006148A/es unknown
- 2021-11-25 EP EP21896013.6A patent/EP4251654A4/en active Pending
- 2021-11-25 AU AU2021386892A patent/AU2021386892A1/en active Pending